Clinical Leaders Reinforce Belief in NGAL for Detection of AKI Following FDA's Decision on BioPorto's The NGAL TestTM
Copenhagen, June 6, 2016 (GLOBE NEWSWIRE) -- In response to the recent FDA decision to decline BioPorto's initial submission for the kidney biomarker neutrophil gelatinase-associated lipocalin (NGAL) as the first diagnostic aid for acute kidney injury …